University of Southern California
The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.
Inclusion Criteria: * APOE ε4 carrier (homozygote or heterozygote) * LDL-C of 100-250 mg/dL * Systolic blood Pressure (SBP) 130-180 mm Hg * Age 50-75 years * Fluency in English * No dementia based on medical record review * Male or post-menopausal female Exclusion Criteria: * One minute standing SBP \< 110 mm Hg * Arm circumference prevents from accurate BP measurement with use of available devices * Lost weight of \> 10% unintendedly (within the past 6 months), * Contraindications to blood pressure and cholesterol lowering medications * Use of medications prescribed for dementia (e.g., adu…
Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes blood pressure management with angiotensin receptor blockers (ARBs).
Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes cholesterol management with hydrophilic statins or a non-statin alternative if statins are not appropriate.
Arctuva estimate
Verify or correct the compensation shown for this listing.